Only weeks after becoming a standalone firm, Sandoz has opened two new European facilities, including a €25m ($27m) biosimilar development center at its location in Holzkirchen, Germany, that it says will “pave the way for the site to become the leading Sandoz analytical characterization center for biosimilars.”
Meanwhile, following a previously announced €150m investment, Sandoz has launched its new facility for the production of penicillin at Kundl,...






